Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04982471 · ClinicalTrials.gov registry record
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
A clinical trial, sponsored by Celgene.
- Terminated
- Registry status
- 36
- Enrollment target
NCT04982471 is a clinical trial that was terminated before completion, run by Celgene. The registered enrollment target is 36 participants.
The verdict
NCT04982471 was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- 36 participants
- Enrollment target
Study Summary
The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, participant-level data longitudinally in participants diagnosed with various subtypes of non-Hodgkin lymphoma (NHL).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-11-03 |
| Est. Completion | 2023-08-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04982471
The ClinicalTrials.gov registry entry for NCT04982471 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04982471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04982471 about?
NCT04982471 is a clinical study titled "Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study". The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, participant-level data longitudinally in participants diagnosed with various subtypes of non-Hodgkin lymphoma (NHL).
What is the current status of trial NCT04982471?
This trial is currently terminated. The enrollment target is 36 participants. The study started on 2021-11-03. Estimated completion is 2023-08-03.
Who is sponsoring clinical trial NCT04982471?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.